Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases, 66730-66731 [2024-18381]
Download as PDF
<![CDATA[
66730
Federal Register / Vol. 89, No. 159 / Friday, August 16, 2024 / Notices
as time permits. Public participants
wishing to offer written comments
should send them to Sahira Rafiullah,
using the contact information above, at
least 3 business days prior to the
meeting. Individuals who plan to attend
either physically or virtually and need
special assistance or other reasonable
accommodation should notify Sahira
Rafiullah through any of the methods
listed above, at least 10 business days
prior to the meeting.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024–18370 Filed 8–15–24; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Eunice Kennedy
Shriver National Institute of Child Health and
Human Development Special Emphasis
Panel; Medical Rehabilitation Research
Resource (P50 Clinical Trial Optional).
Date: November 4–5, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Child Health
and Human Development, 6710B Rockledge
Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Helen Huang, Ph.D.,
Scientific Review Branch, Eunice Kennedy
Shriver National Institute of Child Health
and Human Development, NIH, 6710B
Rockledge Drive, Room 2137D, Bethesda, MD
20892, (301) 496–8558, helen.huang@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
VerDate Sep<11>2014
17:33 Aug 15, 2024
Jkt 262001
Dated: August 13, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2024–18409 Filed 8–15–24; 8:45 am]
Prospective Grant of an Exclusive
Patent License: Dimethyl Synaptamide
for the Treatment of Autoimmune
Disorders and Inflammatory Diseases
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
AGENCY:
National Institutes of Health,
HHS.
National Institutes of Health
ACTION:
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
SUMMARY:
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Interventional Agents Safety
and Pharmacokinetic Services (IASPS).
Date: September 10–13, 2024.
Time: 12:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E70A,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Soheyla Saadi, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3E70A, Rockville, MD
20892, (240) 669–5178, saadisoh@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 13, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–18410 Filed 8–15–24; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Notice.
The National Institute on
Alcohol Abuse and Alcoholism
(NIAAA) and the National Center for
Advancing Translational Sciences
(NCATS), both institutes of the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS),
are contemplating the grant of an
Exclusive Patent License to practice the
inventions embodied in the Patents and
Patent Applications listed in the
Supplementary Information section of
this notice to Autala Bio Inc., A Civala
Company (‘‘Autala’’), incorporated in
Delaware.
Only written comments and/or
applications for a license that are
received by the National Heart Lung and
Blood Institute (NHLBI) Office of
Technology Transfer And Development
(OTTAD) on or before September 3,
2024 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Jillian Varonin, Ph.D.,
Technology Transfer Manager, NHLBI
Office of Technology Transfer And
Development, Telephone: (301) 496–
0505; Email: jillian.varonin@nih.gov.
SUPPLEMENTARY INFORMATION:
DATES:
Intellectual Property
1. United States Provisional Patent
Application No. 61/624,741, filed April
16, 2012, entitled ‘‘Derivatives Of
Docosahexaenoylamide and Uses
Thereof’’ [HHS Reference No. E–070–
2012–0–US–01];
2. PCT Patent Application No. PCT/
US2013/032333, filed March 15, 2013,
entitled ‘‘Derivatives Of
Docosahexaenoylamide and Uses
Thereof’’ [HHS Reference No. E–070–
2012–0–PCT–02];
3. European Patent No. 2847178, filed
March 15, 2013, entitled ‘‘Derivatives Of
Docosahexaenoylamide and Uses
Thereof’’ [HHS Reference No. E–070–
2012–0–EP–03];
4. United States Patent No. 9,422,308,
filed September 23, 2014, entitled
‘‘Derivatives Of Docosahexaenoylamide
E:\FR\FM\16AUN1.SGM
16AUN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 159 / Friday, August 16, 2024 / Notices
and Uses Thereof’’ [HHS Reference No.
E–070–2012–0–US–04];
5. Germany Patent No.
602013016154.2, filed October 30, 2014,
entitled ‘‘Derivatives Of
Docosahexaenoylamide and Uses
Thereof’’ [HHS Reference No. E–070–
2012–0–DE–05];
6. France Patent No. 2847178, filed
October 30, 2014, entitled ‘‘Derivatives
Of Docosahexaenoylamide and Uses
Thereof’’ [HHS Reference No. E–070–
2012–0–FR–06];
7. Great Britain Patent No. 2847178,
filed October 30, 2014, entitled
‘‘Derivatives Of Docosahexaenoylamide
and Uses Thereof’’ [HHS Reference No.
E–070–2012–0–GB–07].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to the
following:
‘‘Use of a G-protein-coupled receptor
110 (‘‘GPR110’’) agonist named
dimethyl synaptamide (‘‘DMS’’) (also
known as Compound NCGC00248435;
(4Z,7Z,10Z,13Z,16Z,19Z)-N-(2-hydroxy2-methylpropyl) docosa-4,7,10,13,16,19hexaenamide; or ‘‘A8’’) to treat multiple
sclerosis (‘‘MS’’), chronic inflammatory
demyelinating polyradiculoneuropathy
(‘‘CIDP’’), psoriasis, inflammatory bowel
disease (‘‘IBD’’), Crohn’s disease,
ulcerative colitis (‘‘UC’’), sclerosing
cholangitis, ankylosing spondylitis,
rheumatoid arthritis (‘‘RA’’), psoriatic
arthritis, systemic lupus erythematosus
(‘‘SLE’’), lupus nephritis, sarcoidosis,
and Behcet’s disease.’’
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the NHLBI Office
of Technology Transfer And
Development receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
VerDate Sep<11>2014
17:33 Aug 15, 2024
Jkt 262001
66731
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Bruce D. Goldstein,
Director, Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
Dated: August 13, 2024
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–18381 Filed 8–15–24; 8:45 am]
[FR Doc. 2024–18412 Filed 8–15–24; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
National Institute of Dental &
Craniofacial Research; Notice of
Partially Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Respiratory Sciences.
Date: September 9, 2024.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Michael L. Bloom, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6187,
MSC 7804, Bethesda, MD 20892, 301–451–
0132, bloomm2@mail.nih.gov.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group;
Biobehavioral Medicine and Health
Outcomes Study Section.
Date: September 19–20, 2024.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mark A. Vosvick, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110,
Bethesda, MD 20892, (301) 402–4128,
mark.vosvick@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory Dental
and Craniofacial Research Council.
The meeting will be held as a virtual
meeting and is partially open to the
public as indicated below. Individuals
who plan to view the virtual meeting
and need special assistance to view the
meeting, such as sign language
interpretation or other reasonable
accommodations, should notify the
Contact Person listed below in advance
of the meeting. The open session will be
videocast and can be accessed from the
NIH Videocasting website (https://
videocast.nih.gov/). Registration is not
required to access the videocast.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National
Advisory Dental and Craniofacial
Research Council.
Date: September 11, 2024.
Open: 10:00 a.m. to 3:15 p.m.
Agenda: Report of the Director,
NIDCR and concept clearances.
Place: National Institute of Dental &
Craniofacial Research, 6701 Democracy
Boulevard, Bethesda, MD 20892,
(Virtual Meeting).
Closed: 3:30 p.m. to 4:15 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Dental &
Craniofacial Research, 6701 Democracy
Boulevard, Bethesda, MD 20892,
(Virtual Meeting).
E:\FR\FM\16AUN1.SGM
16AUN1
]]>Agencies
[Federal Register Volume 89, Number 159 (Friday, August 16, 2024)]
[Notices]
[Pages 66730-66731]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-18381]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Dimethyl
Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory
Diseases
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute on Alcohol Abuse and Alcoholism (NIAAA)
and the National Center for Advancing Translational Sciences (NCATS),
both institutes of the National Institutes of Health (NIH), Department
of Health and Human Services (HHS), are contemplating the grant of an
Exclusive Patent License to practice the inventions embodied in the
Patents and Patent Applications listed in the Supplementary Information
section of this notice to Autala Bio Inc., A Civala Company
(``Autala''), incorporated in Delaware.
DATES: Only written comments and/or applications for a license that are
received by the National Heart Lung and Blood Institute (NHLBI) Office
of Technology Transfer And Development (OTTAD) on or before September
3, 2024 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Jillian Varonin, Ph.D., Technology Transfer
Manager, NHLBI Office of Technology Transfer And Development,
Telephone: (301) 496-0505; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. United States Provisional Patent Application No. 61/624,741,
filed April 16, 2012, entitled ``Derivatives Of Docosahexaenoylamide
and Uses Thereof'' [HHS Reference No. E-070-2012-0-US-01];
2. PCT Patent Application No. PCT/US2013/032333, filed March 15,
2013, entitled ``Derivatives Of Docosahexaenoylamide and Uses Thereof''
[HHS Reference No. E-070-2012-0-PCT-02];
3. European Patent No. 2847178, filed March 15, 2013, entitled
``Derivatives Of Docosahexaenoylamide and Uses Thereof'' [HHS Reference
No. E-070-2012-0-EP-03];
4. United States Patent No. 9,422,308, filed September 23, 2014,
entitled ``Derivatives Of Docosahexaenoylamide
[[Page 66731]]
and Uses Thereof'' [HHS Reference No. E-070-2012-0-US-04];
5. Germany Patent No. 602013016154.2, filed October 30, 2014,
entitled ``Derivatives Of Docosahexaenoylamide and Uses Thereof'' [HHS
Reference No. E-070-2012-0-DE-05];
6. France Patent No. 2847178, filed October 30, 2014, entitled
``Derivatives Of Docosahexaenoylamide and Uses Thereof'' [HHS Reference
No. E-070-2012-0-FR-06];
7. Great Britain Patent No. 2847178, filed October 30, 2014,
entitled ``Derivatives Of Docosahexaenoylamide and Uses Thereof'' [HHS
Reference No. E-070-2012-0-GB-07].
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the following:
``Use of a G-protein-coupled receptor 110 (``GPR110'') agonist
named dimethyl synaptamide (``DMS'') (also known as Compound
NCGC00248435; (4Z,7Z,10Z,13Z,16Z,19Z)-N-(2-hydroxy-2-methylpropyl)
docosa-4,7,10,13,16,19-hexaenamide; or ``A8'') to treat multiple
sclerosis (``MS''), chronic inflammatory demyelinating
polyradiculoneuropathy (``CIDP''), psoriasis, inflammatory bowel
disease (``IBD''), Crohn's disease, ulcerative colitis (``UC''),
sclerosing cholangitis, ankylosing spondylitis, rheumatoid arthritis
(``RA''), psoriatic arthritis, systemic lupus erythematosus (``SLE''),
lupus nephritis, sarcoidosis, and Behcet's disease.''
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the NHLBI
Office of Technology Transfer And Development receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part
404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Bruce D. Goldstein,
Director, Office of Technology Transfer and Development, National
Heart, Lung, and Blood Institute.
[FR Doc. 2024-18381 Filed 8-15-24; 8:45 am]
BILLING CODE 4140-01-P
